Latest NewsNov 4, 2024HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200604, a Best-in-Class BTLA Agonist Antibody for the Treatment of Inflammatory and Immunology Diseases All Filter By: Year2024202320222021202020192018201720162015Apr 18, 2022HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatmentApr 18, 2022Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumorsApr 18, 2022Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterizationApr 4, 2022HiFiBiO Therapeutics Announces Three Presentations at 2022 American Association for Cancer Research (AACR) Annual MeetingJan 10, 2022HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB301001< 1 … 4 5 6 7 8 … 17 >
